Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Preclinical and retrospective studies suggest that beta-blockers are active against breast cancer. We carried out a systematic review and meta-analysis to assess the impact of beta-blockers on the outcomes of patients with early-stage breast cancer.

Methods

A systematic literature search was performed to identify studies comparing outcomes of patients with early-stage breast cancer according to beta-blocker use (yes versus no). The primary endpoint was recurrence-free survival (RFS), defined as the occurrence of breast cancer recurrence or death. Secondary objectives were pathologic complete response (pCR), breast cancer recurrence, breast cancer-specific mortality and overall survival (OS). Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CI

SUBMITTER: Caparica R 

PROVIDER: S-EPMC7921512 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature